A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19
Clinical trial NCT05172141 · TERMINATED
Trial details
- NCT number
- NCT05172141
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-31
- Primary completion
- 2022-08-31
- Enrollment
- 222
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.